MSK's PathoMAN achieved 94 percent and 81 percent concordance with results from three commercial labs for pathogenic and benign variants, respectively.
The machine-learning-based method identifies relationships between bacterial strains and tracks their movements in less time, using less memory than existing solutions.
The company has begun piloting the software, which is targeted towards bioinformatics companies and clinical laboratories, with early adopters ahead of the planned launch.
Results from a recent study suggest that considering nearby variants can improve the accuracy of neoantigen selection, resulting in better personalized vaccines for patients.
The planned product, which will target drug-development companies, uses machine learning techniques to predict the outcomes and likelihood of success of clinical trials.
Five months after a name change, the former Lab7 Systems has evolved its technology into an app-based platform to support NGS, translational research, and cell therapy.
In addition to the federal grant, the startup has received $125,000 from a Michigan technology fund to help commercialize its GPU-based analysis platform.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.
